Improved care has extended lifespan of childhood cancer survivors since the 1970s

New targeted treatments for blood cancers: Multiple myeloma, non-Hodgkin lymphoma, genomic marker mismatch repair and myelofibrosis

Targeted drug daratumumab shows promise in heavily treatment-resistant multiple myeloma

Ibrutinib combination regimen shows substantial benefits in relapsed CLL

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrozole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Extensive lymph node surgery may not be necessary for some patients with melanoma

Effective adjuvant chemotherapy for high-risk, localised prostate cancer

Novel JAK inhibitor pacritinib proving effective for easing symptoms of myelofibrosis

Novel targeted drug palbociclib slows progression of hormone receptor-positive breast cancer

Anastrazole offers higher breast cancer-free survival rates than tamoxifen following DCIS

Eribulin extends overall survival for patients with advanced liposarcoma and leiomyosarcoma